Can Stryker Justify Optimism After Cyber Disruption and Implant Demand Softness?

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Stryker reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to react to actual earnings.

Stryker's post-earnings price behavior shows significant volatility, with an average absolute Day +1 move of 2.78% following earnings releases. The Day +1 reactions have been notably larger than Day 0 moves (which average just 0.75%), reflecting how the market waits for actual results before making major positioning changes.

Looking at recent history, the Day +1 moves have been substantial and predominantly negative. The most recent Q1 2026 report triggered a -6.47% decline — the largest single-day drop in the dataset — following the significant earnings miss. Prior quarters showed more mixed but still meaningful reactions: +4.31% after Q4 2025, -3.45% after Q3 2025, and -3.80% after Q2 2025.

The average Day +1 range of 3.95% indicates investors should prepare for meaningful price swings regardless of direction. The stock has demonstrated it can move sharply in either direction based on results, with recent volatility skewing negative as the company has faced execution challenges. Given the elevated expectations heading into this report (with estimates revised significantly higher), the potential for another outsized move exists if results deviate meaningfully from the $3.46 consensus.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.85% expected move for this earnings release, significantly larger than the historical average Day +1 move of 2.78%. This elevated implied volatility suggests options traders are anticipating a more dramatic reaction than typical, likely reflecting uncertainty about whether Stryker can rebound from Q1's significant miss and the heightened stakes given recent estimate revisions.

Part 3: What Analysts Are Saying

Analyst sentiment on Stryker remains strongly bullish despite recent execution challenges. The consensus rating stands at 4.48 out of 5.0, with 20 Strong Buy ratings, 3 Moderate Buys, and 6 Hold ratings — no analysts recommend selling the stock. This represents an improved outlook, with sentiment trending positively as two analysts upgraded to Strong Buy over the past month.

The average price target of $382.04 implies 8.5% upside from the current price of $352.25, suggesting analysts see the recent weakness as a buying opportunity rather than a fundamental deterioration. Price targets range from a low of $315.00 to a high of $455.00, with the wide range reflecting differing views on how quickly the company can return to its historical growth trajectory.

The sentiment improvement is notable given Q1's disappointing results. Rather than downgrading following the miss, analysts have largely maintained or strengthened their positive stance, with 23 of 29 analysts (79%) rating the stock a buy or strong buy. This suggests the analyst community views Q1 as an aberration and expects the company's strong market positions in orthopedics, surgical equipment, and neurotechnology to drive continued long-term growth. The consensus appears to be that Stryker's fundamental competitive advantages remain intact despite near-term execution challenges.

Part 4: Technical Picture

Stryker's technical setup heading into earnings shows improving momentum after recovering from Q1's sharp decline. The Barchart Technical Opinion currently reads 24% Buy, a dramatic reversal from last week's 72% Sell signal and last month's 56% Sell reading. This rapid shift reflects the stock's strong recent rally back toward previous highs.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has turned positive as the stock rebounds from recent lows
• Medium-term (50% Sell): Neutral-to-negative reading suggests some caution remains in the intermediate timeframe as investors assess whether the recovery is sustainable
• Long-term (50% Buy): Moderate buy signal reflects confidence in the longer-term uptrend despite recent volatility

Trend Characteristics: The weak strength combined with average direction suggests the stock is in a transitional phase, recovering from Q1's setback but not yet establishing a convincing new uptrend.

At $352.25, Stryker trades above its 5-day ($336.96), 10-day ($327.88), 20-day ($325.80), 50-day ($316.34), and 100-day ($321.86) moving averages, but remains above its 200-day moving average of $343.45. This positioning above all shorter-term averages demonstrates strong recent momentum, though the stock is still working to reclaim its longer-term trend line.

The technical setup presents a mixed picture heading into earnings. While the stock has recovered impressively from Q1's decline and now trades above most key moving averages, the proximity to the 200-day moving average at $343.45 means the stock lacks significant technical cushion if results disappoint again. The rapid improvement in short-term signals suggests positive momentum, but the 6.85% expected move implies substantial two-way risk. A strong earnings beat could propel the stock decisively above the 200-day average and toward the $382 analyst price target, while another miss could quickly reverse recent gains and test support in the $320-$330 range where the 20-day through 100-day moving averages cluster.